| Literature DB >> 31658252 |
Valerie A Paz-Soldan1,2, Amy C Morrison3,4, Heng Sopheab5, Julia Schwarz6, Karin M Bauer1,7, Jennie L Mckenney8, Chhorvann Chhea5, Vonthanak Saphonn9, Dyna Khuon9, Robert D Hontz4,10, Pamina M Gorbach8.
Abstract
In 2012, the U.S. Defense Threat Reduction Agency Joint Science and Technology Office initiated a program to develop novel point-of-need diagnostic devices for surveillance of emerging infectious diseases including dengue, malaria, plague, and melioidosis. Prior to distribution of devices to observe their correct use among community members in Iquitos, Peru, and Phnom Penh, Cambodia, research was conducted to: 1) assess acceptability of use, including the motivation to use a rapid diagnostic test (RDT) before or instead of seeking care at a health facility, 2) explore comprehension of RDT use instructions, and 3) examine possible strategies for large scale RDT distribution and use at each site. In February 2014, 9 focus group discussions (FGD) with community members and 5 FGD with health professionals were conducted in Iquitos, and 9 FGD with community members and 9 in-depth interviews with health professionals in Phnom Penh. In both places, participants agreed to use the device themselves (involving finger prick) or could identify someone who could do so in their home or neighborhood. The main incentive to RDT use in both sites was the ability for device results to be used for care facilitation (post confirmatory tests), specifically reduced wait times to be seen or obtain a diagnosis. Comprehension of RDT use instructions was assessed in Iquitos by asking some participants to apply the device to research team members; after watching a short video, most steps were done correctly. In Phnom Penh, participants were asked to describe each step after reading the instructions; they struggled with comprehension. Health professionals' main concerns in both sites were their community's ability to accurately use the test, handle complicated instructions, and safety (i.e., disposal of lancets). Health system structure and ability to use home diagnostic devices varied in the two disease endemic sites, with substantial challenges in each, suggesting the need for different strategies for RDT large scale community use, and illustrating the value of formative research before deployment of novel technologies.Entities:
Mesh:
Year: 2019 PMID: 31658252 PMCID: PMC6837536 DOI: 10.1371/journal.pntd.0007773
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Summary of FGDs and IDIs conducted in Peru and Cambodia.
| FGD | IDI | ||
|---|---|---|---|
| Number of FGDs | Number of Participants | Number of Participants | |
| Community members (in Proyecto Dengue study area) | 5 | 45 | - |
| Community members (outside Proyecto Dengue study area) | 4 | 30 | - |
| Doctors | 1 | 6 | - |
| Nurses | 2 | 16 | - |
| Nurses involved in febrile study | 1 | 5 | - |
| Medical students | 1 | 14 | - |
| Community members | 6 | 36 | - |
| Village health workers | 3 | 19 | - |
| Fever investigation team | - | - | 2 |
| Health Center staff | - | - | 2 |
| National Malaria Center (CNM) | - | - | 2 |
| National Institute of Public Health (lab staff) | - | - | 2 |
| Private pharmacy staff | - | - | 1 |
Fig 1Written instructions in Spanish that were provided to focus group participants in Peru.
Fig 2Preference for documenting observed results on paper based on what focus group participants viewed on rapid diagnostic test, in Spanish.
Fig 3Written instruction in Khmer and demonstration of the test kit in Cambodia.
Summary of demographic characteristics of people participating in the community focus group discussions in Iquitos, Peru.
| FG N° | N° participants | Sex | Age | Knows how to use a thermometer | Would use the test on themselves | Would you use | Estimated price participants would pay for a device | |
|---|---|---|---|---|---|---|---|---|
| F | M | |||||||
| 1 | 10 | 10 | 0 | 27–45 | 2 | 10 | 7 | -- |
| 2 | 10 | 6 | 4 | 18–60 | 0 | 6 | 10 | 1.75 |
| 3 | 8 | 8 | 0 | 23–37 | 0 | 7 | 6 | 1.75 |
| 4 | 9 | 9 | 0 | 30–48 | 2 | 8 | 9 | 1.75 |
| 5 | 8 | 8 | 0 | 22–40 | 2 | 8 | 7 | 1.75 |
| 6 | 8 | 8 | 0 | 26–54 | 1 | 7 | 8 | 1.75 |
| 7 | 6 | 5 | 1 | 33–52 | -- | 6 | 6 | 1.75 |
| 8 | 8 | 8 | 0 | 20–44 | 0 | 3 | 2 | 1.75 |
| 9 | 8 | 8 | 0 | 22–42 | -- | 8 | 8 | -- |